Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6852338 | 1.00 | TAAR1 (0.53) | TAAR1SLC18A2SIGMAR1CAPN1MEN1 | |
| SCHEMBL2920753 | 1.00 | TAAR1 (0.53) | TAAR1SLC18A2SIGMAR1CAPN1MEN1 | |
| SCHEMBL15203095 | 0.89 | ACE (0.47) | TAAR1SLC18A2SIGMAR1CAPN1MEN1 | |
| SCHEMBL24153337 | 0.89 | ACE (0.47) | TAAR1SLC18A2SIGMAR1CAPN1MEN1 | |
| SCHEMBL17167138 | 0.84 | CAPN1 (0.60) | CAPN1ACECTSB | |
| SCHEMBL21654011 | 0.83 | CAPN1 (0.49) | TAAR1SLC18A2SIGMAR1CAPN1MEN1 | |
| SCHEMBL13599518 | 0.82 | CAPN1 (0.38) | CAPN1ACE | |
| SCHEMBL10167782 | 0.82 | ACE (0.53) | TAAR1CAPN1MEN1KMT2AACE | |
| SCHEMBL13489139 | 0.82 | ACE (0.53) | TAAR1CAPN1MEN1KMT2AACE | |
| SCHEMBL12803090 | 0.82 | ACE (0.53) | TAAR1CAPN1MEN1KMT2AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194737-A1 | Hepta-, octa-and nonapeptides having antiangiogenic activity | HAVIV FORTUNA | 2006-08-31 | — | — | US | claimed |
| US-7067490-B2 | Hepta-, Octa-and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-06-27 | — | — | US | claimed |
| EP-1451210-A2 | HEPTA-, OCTA- AND NONAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2004-09-01 | — | — | EP | claimed |
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | claimed |
| US-6632795-B1 | Treatment of cancer | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-14 | — | — | US | claimed |
| US-20030109455-A1 | HEPTA-, OCTA-and nonapeptides having antiangiogenic activity | ABBVIE INC. | 2003-06-12 | — | — | US | claimed |
| EP-0981358-B1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AG (DE) | 2003-05-28 | — | — | EP | claimed |
| US-20030096758-A1 | HEPTA-, OCTA- and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-05-22 | — | — | US | claimed |
| WO-2003037268-A2 | HEPTA-, OCTA- AND NONAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-05-08 | — | — | WO | claimed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | claimed |
| EP-0480918-A4 | REDUCED SIZE LHRH ANALOGS. | ABBOTT LAB (US) | 1991-06-04 | — | — | EP | claimed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | claimed |
| EP-0400065-A4 | LHRH ANALOGS | — | 1991-03-13 | — | — | EP | claimed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | claimed |
| EP-0400065-A1 | LHRH ANALOGS. | ABBOTT LAB (US) | 1990-12-05 | — | — | EP | claimed |
| EP-0390181-A2 | Perylenequinone (UCN-1028D) derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-10-03 | — | — | EP | claimed |
| WO-1989007450-A1 | LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| WO-1989007451-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328089-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| EP-0328090-A2 | LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |